Abstract
Activation of the tumour suppressor p53 by DNA damage induces either cell cycle arrest or apoptotic cell death1. The cytostatic effect of p53 is mediated by transcriptional activation of the cyclin-dependent kinase (CDK) inhibitor p21Cip1, whereas the apoptotic effect is mediated by transcriptional activation of mediators including PUMA and PIG3 (ref. 2). What determines the choice between cytostasis and apoptosis is not clear3. Here we show that the transcription factor Myc is a principal determinant of this choice. Myc is directly recruited to the p21Cip1 promoter by the DNA-binding protein Miz-1. This interaction blocks p21Cip1 induction by p53 and other activators. As a result Myc switches, from cytostatic to apoptotic, the p53-dependent response of colon cancer cells to DNA damage. Myc does not modify the ability of p53 to bind to the p21Cip1 or PUMA promoters, but selectively inhibits bound p53 from activating p21Cip1 transcription. By inhibiting p21Cip1 expression Myc favours the initiation of apoptosis, thereby influencing the outcome of a p53 response in favour of cell death.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307–310 (2000)
Vousden, K. H. & Lu, X. Live or let die: the cell's response to p53. Nature Rev. Cancer 2, 594–604 (2002)
Lane, D. How cells choose to die. Nature 414, 25–27 (2001)
Grandori, C., Cowley, S. M., James, L. P. & Eisenman, R. N. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 16, 653–699 (2000)
Alexandrow, M. G., Kawabata, M., Aakre, M. & Moses, H. L. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1. Proc. Natl Acad. Sci. USA 92, 3239–3243 (1995)
Mitchell, K. O. & El-Deiry, W. S. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ. 10, 223–230 (1999)
Claassen, G. F. & Hann, S. R. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor-β-induced cell-cycle arrest. Proc. Natl Acad. Sci. USA 97, 9498–9503 (2000)
Warner, B. J., Blain, S. W., Seoane, J. & Massague, J. Myc downregulation by transforming growth factor β required for activation of the p15Ink4B G1 arrest pathway. Mol. Cell. Biol. 19, 5913–5922 (1999)
Datto, M. B., Yu, Y. & Wang, X.-F. Functional analysis of the transforming growth factor β responsive elements in WAF1/Cip1/p21 promoter. J. Biol. Chem. 270, 28623–28628 (1995)
El-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumour suppression. Cell 75, 817–825 (1993)
Zeng, Y. X. & el-Deiry, W. S. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 12, 1557–1564 (1996)
Massague, J., Blain, S. W. & Lo, R. S. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103, 295–309 (2000)
Zeng, Y. X., Somasundaram, K. & el-Deiry, W. S. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nature Genet. 15, 78–82 (1997)
Biggs, J. R., Kudlow, J. E. & Kraft, A. S. The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J. Biol. Chem. 271, 901–906 (1996)
Waldman, T., Kinzler, K. W. & Vogelstein, B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55, 5187–5190 (1995)
Bunz, F. et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497–1501 (1998)
Gewirtz, D. A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57, 727–741 (1999)
Resnick-Silverman, L., St Clair, S., Maurer, M., Zhao, K. & Manfredi, J. J. Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumour suppressor protein p53. Genes Dev. 12, 2102–2107 (1998)
Zawel, L. et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1, 611–617 (1998)
Staller, P. et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nature Cell Biol. 3, 392–399 (2001)
Seoane, J. et al. TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nature Cell Biol. 3, 400–408 (2001)
Ziegelbauer, J. et al. Transcription factor MIZ-1 is regulated via microtubule association. Mol. Cell 8, 339–349 (2001)
Zindy, F. et al. Myc signaling via the ARF tumour suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12, 2424–2433 (1998)
Burri, N. et al. Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer. Lab. Invest. 81, 217–229 (2001)
Polyak, K., Waldman, T., He, T. C., Kinzler, K. W. & Vogelstein, B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10, 1945–1952 (1996)
Reynisdottir, I., Polyak, K., Iavarone, A. & Massague, J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev. 9, 1831–1845 (1995)
Peukert, K. et al. An alternative pathway for gene regulation by Myc. EMBO J. 16, 5672–5686 (1997)
Li, J. M., Nichols, M. A., Chandrasekharan, S., Xiong, Y. & Wang, X. F. Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. J. Biol. Chem. 270, 26750–26753 (1995)
Hata, A. et al. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. Cell 100, 229–240 (2000)
Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A. & Brown, M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103, 843–852 (2000)
Acknowledgements
We thank W. El-Deiry and S. Lowe for providing the recombinant adenovirus; B. Vogelstein and K. Kinzler for the HCT116 cell lines and the PUMA antibody; M. Eilers for Miz constructs; R. Tjian for the Miz-1 antibody and the bacterial expression vector encoding Miz-1; and S. Blain for advice. We also thank D. Domingo and the Memorial Sloan-Kettering flow cytometry core facility for their help in the FACS analysis. J.M. is an Investigator of the Howard Hughes Medical Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare that they have no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Seoane, J., Le, HV. & Massagué, J. Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419, 729–734 (2002). https://doi.org/10.1038/nature01119
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature01119
This article is cited by
-
PAF1c links S-phase progression to immune evasion and MYC function in pancreatic carcinoma
Nature Communications (2024)
-
Outsmarting trogocytosis to boost CAR NK/T cell therapy
Molecular Cancer (2023)
-
The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin’s lymphoma tumor growth by promoting apoptosis and autophagy
Cell Communication and Signaling (2023)
-
HDAC7/c-Myc signaling pathway promotes the proliferation and metastasis of choroidal melanoma cells
Cell Death & Disease (2023)
-
RUNX3 inactivates oncogenic MYC through disruption of MYC/MAX complex and subsequent recruitment of GSK3β-FBXW7 cascade
Communications Biology (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.